Ya-long Feng

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/99322/publications.pdf

Version: 2024-02-01

26 papers 2,585 citations

279701 23 h-index 27 g-index

27 all docs

27 docs citations

times ranked

27

2641 citing authors

#	Article	IF	CITATIONS
1	New insights into TGF- \hat{l}^2 /Smad signaling in tissue fibrosis. Chemico-Biological Interactions, 2018, 292, 76-83.	1.7	671
2	Central role of dysregulation of TGF- $\hat{1}^2$ /Smad in CKD progression and potential targets of its treatment. Biomedicine and Pharmacotherapy, 2018, 101, 670-681.	2. 5	250
3	Natural Products as a Source for Antifibrosis Therapy. Trends in Pharmacological Sciences, 2018, 39, 937-952.	4.0	162
4	Microbiome–metabolomics reveals gut microbiota associated with glycine-conjugated metabolites and polyamine metabolism in chronic kidney disease. Cellular and Molecular Life Sciences, 2019, 76, 4961-4978.	2.4	146
5	Ultra Performance Liquid Chromatography-Based Metabonomic Study of Therapeutic Effect of the Surface Layer of Poria cocos on Adenine-Induced Chronic Kidney Disease Provides New Insight into Anti-Fibrosis Mechanism. PLoS ONE, 2013, 8, e59617.	1.1	105
6	Urinary metabonomic study of the surface layer of Poria cocos as an effective treatment for chronic renal injury in rats. Journal of Ethnopharmacology, 2013, 148, 403-410.	2.0	94
7	Traditional uses, phytochemistry, pharmacology, pharmacokinetics and quality control of Polyporus umbellatus (Pers.) Fries: A review. Journal of Ethnopharmacology, 2013, 149, 35-48.	2.0	93
8	Small molecule inhibitors of epithelialâ€mesenchymal transition for the treatment of cancer and fibrosis. Medicinal Research Reviews, 2020, 40, 54-78.	5.0	93
9	Natural products for the prevention and treatment of kidney disease. Phytomedicine, 2018, 50, 50-60.	2.3	92
10	Unilateral ureteral obstruction causes gut microbial dysbiosis and metabolome disorders contributing to tubulointerstitial fibrosis. Experimental and Molecular Medicine, 2019, 51, 1-18.	3.2	90
11	Diuretic activity of some fractions of the epidermis of Poria cocos. Journal of Ethnopharmacology, 2013, 150, 1114-1118.	2.0	86
12	Metabolomics in Dyslipidemia. Advances in Clinical Chemistry, 2014, 66, 101-119.	1.8	79
13	Poricoic acid A enhances melatonin inhibition of AKI-to-CKD transition by regulating Gas6/Axl NF κB/Nrf2 axis. Free Radical Biology and Medicine, 2019, 134, 484-497.	1.3	76
14	Diuretic activity of the ethanol and aqueous extracts of the surface layer of Poria cocos in rat. Journal of Ethnopharmacology, 2012, 144, 775-778.	2.0	73
15	Diuretic and anti-diuretic activities of fractions of Alismatis rhizoma. Journal of Ethnopharmacology, 2014, 157, 114-118.	2.0	70
16	Renal metabolic profiling of early renal injury and renoprotective effects of Poria cocos epidermis using UPLC Q-TOF/HSMS/MSE. Journal of Pharmaceutical and Biomedical Analysis, 2013, 81-82, 202-209.	1.4	69
17	Diuretic and anti-diuretic activities of the ethanol and aqueous extracts of Alismatis rhizoma. Journal of Ethnopharmacology, 2014, 154, 386-390.	2.0	64
18	Identification of endogenous 1â€aminopyrene as a novel mediator of progressive chronic kidney disease via aryl hydrocarbon receptor activation. British Journal of Pharmacology, 2020, 177, 3415-3435.	2.7	50

#	Article	IF	CITATIONS
19	Dietary natural flavonoids treating cancer by targeting aryl hydrocarbon receptor. Critical Reviews in Toxicology, 2019, 49, 445-460.	1.9	44
20	Aryl hydrocarbon receptor activation mediates kidney disease and renal cell carcinoma. Journal of Translational Medicine, 2019, 17, 302.	1.8	42
21	Activated NF- \hat{l}^{P} B/Nrf2 and Wnt/ \hat{l}^{2} -catenin pathways are associated with lipid metabolism in CKD patients with microalbuminuria and macroalbuminuria. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 2317-2332.	1.8	42
22	Pharmacokinetics of 2,3,5,4′â€ŧetrahydroxystilbeneâ€2â€ <scp>O</scp> â€Î²â€ <scp>D</scp> â€glucoside in raultraâ€performance <scp>LC</scp> â€quadrupole <scp>TOF</scp> â€ <scp>MS</scp> . Journal of Separation Science, 2013, 36, 863-871.	at using 1.3	37
23	The Matrix Metalloproteinaseâ€13 Inhibitor Poricoic Acid ZI Ameliorates Renal Fibrosis by Mitigating Epithelialâ€Mesenchymal Transition. Molecular Nutrition and Food Research, 2019, 63, e1900132.	1.5	33
24	Small molecules against the origin and activation of myofibroblast for renal interstitial fibrosis therapy. Biomedicine and Pharmacotherapy, 2021, 139, 111386.	2.5	11
25	Cloud-Point Extraction Combined with Liquid Chromatography for the Determination of Ergosterol, a Natural Product with Diuretic Activity, in Rat Plasma, Urine, and Faeces. Journal of Analytical Methods in Chemistry, 2013, 2013, 1-8.	0.7	6
26	MicroRNAs in organ fibrosis: From molecular mechanisms to potential therapeutic targets. Pathology Research and Practice, 2021, 225, 153588.	1.0	4